share_log

Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1

レクサリアは、糖尿病と減量の動物実験を開始する予定です。WEIGHT-A24-1

Benzinga ·  03/05 09:10
  • Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
  • Chronic dosing over a 12-week treatment period
  • Will assess weight loss and blood glucose level control
  • Efficacy through possible brain absorption delivery enhancement to be assessed

KELOWNA, BC / ACCESSWIRE / March 5, 2024 /Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal studyWEIGHT-A24-1(the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.

The contract for the Study has been awarded to...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする